TW281671B - - Google Patents

Info

Publication number
TW281671B
TW281671B TW083110934A TW83110934A TW281671B TW 281671 B TW281671 B TW 281671B TW 083110934 A TW083110934 A TW 083110934A TW 83110934 A TW83110934 A TW 83110934A TW 281671 B TW281671 B TW 281671B
Authority
TW
Taiwan
Prior art keywords
pct
inhibitors
sec
date
date jul
Prior art date
Application number
TW083110934A
Other languages
English (en)
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of TW281671B publication Critical patent/TW281671B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW083110934A 1993-11-29 1994-11-24 TW281671B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15866193A 1993-11-29 1993-11-29

Publications (1)

Publication Number Publication Date
TW281671B true TW281671B (zh) 1996-07-21

Family

ID=22569128

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083110934A TW281671B (zh) 1993-11-29 1994-11-24

Country Status (20)

Country Link
US (1) US5668143A (zh)
EP (1) EP0731792B1 (zh)
JP (1) JP3612073B2 (zh)
KR (1) KR100351884B1 (zh)
CN (1) CN1045596C (zh)
AT (1) ATE176225T1 (zh)
AU (1) AU682736B2 (zh)
CA (1) CA2177146C (zh)
DE (1) DE69416324T2 (zh)
DK (1) DK0731792T3 (zh)
ES (1) ES2129794T3 (zh)
FI (1) FI113368B (zh)
GR (1) GR3029485T3 (zh)
HU (1) HU222819B1 (zh)
IL (1) IL111774A (zh)
NO (1) NO306158B1 (zh)
NZ (1) NZ276570A (zh)
TW (1) TW281671B (zh)
WO (1) WO1995014670A1 (zh)
ZA (1) ZA949301B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684017A (en) * 1993-11-29 1997-11-04 Merrell Pharmaceuticals Inc. Benzenesulfonylimine derivatives as inhibitors of IL-1 action
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
AU2002345796A1 (en) * 2001-06-26 2003-03-03 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
KR100687522B1 (ko) * 2005-05-28 2007-02-27 한국화학연구원 2,2-디메틸-3-에스테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제
WO2013061151A2 (en) 2011-10-28 2013-05-02 Alfred Iseli Method and device for manufacturing ultralight cardboard structures having substantial mechanical stability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
CA2104297C (en) * 1991-02-27 2003-05-27 Boyd Lynn Harrison 4-sulfanimide-quinoline nmda antagonists
JPH05331169A (ja) * 1992-05-26 1993-12-14 Sumitomo Pharmaceut Co Ltd ベンゾナフチリジン誘導体

Also Published As

Publication number Publication date
NO306158B1 (no) 1999-09-27
US5668143A (en) 1997-09-16
EP0731792A1 (en) 1996-09-18
HU222819B1 (hu) 2003-11-28
ES2129794T3 (es) 1999-06-16
GR3029485T3 (en) 1999-05-28
HU9601434D0 (en) 1996-07-29
DK0731792T3 (da) 1999-09-13
NZ276570A (en) 2001-02-23
DE69416324D1 (de) 1999-03-11
CA2177146A1 (en) 1995-06-01
IL111774A0 (en) 1995-01-24
JP3612073B2 (ja) 2005-01-19
WO1995014670A1 (en) 1995-06-01
AU1086895A (en) 1995-06-13
CN1136312A (zh) 1996-11-20
JPH09506344A (ja) 1997-06-24
NO962156L (no) 1996-05-28
AU682736B2 (en) 1997-10-16
FI962236A0 (fi) 1996-05-28
CA2177146C (en) 1999-07-06
ATE176225T1 (de) 1999-02-15
ZA949301B (en) 1995-08-07
KR100351884B1 (ko) 2002-12-31
CN1045596C (zh) 1999-10-13
DE69416324T2 (de) 1999-06-10
HUT76272A (en) 1997-07-28
IL111774A (en) 1999-11-30
NO962156D0 (no) 1996-05-28
FI962236A (fi) 1996-05-28
EP0731792B1 (en) 1999-01-27
FI113368B (fi) 2004-04-15

Similar Documents

Publication Publication Date Title
GR3032506T3 (en) 3-aryl-2-isoxazolines as antiinflammatory agents
EG20693A (en) Isoxazoline compounds as antiinflammatory agents
BR9407239A (pt) Azadioxacicloalquenos substituídos
TW279161B (zh)
TW281671B (zh)
AU4623396A (en) 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
FI962301A0 (fi) Substituoidut aminoalkyyliaminopyridiinit